Braeburn is developing long-acting medicines for treating opioid addiction.
Opioid addiction is a medical condition requiring medical treatment. Together with counseling and support, Braeburn’s next generation medicines allow patients to focus on the reintegration of their lives and communities. Braeburn’s products are positioned to provide a key solution in treating OUD (opioid use disorder). Braeburn’s long-acting formulations are intended to be administered by the healthcare professional. Administration by healthcare professionals ensures delivery and medication adherence while potentially minimizing risks of diversion, misuse, and accidental pediatric exposure.
Braeburn develops next generation pharmaceuticals for opioid addiction treatment.
The focus of Braeburn is primarily on opioid dependence but it is also our aim to address other therapeutic areas in pain where our competence and technologies can create value.
Our product pipeline targets opioid use disorder, with CAM2038 weekly and CAM2038 monthly formulations. CAM2038 is an investigational extended-release buprenorphine injection for subcutaneous administration. CAM2038’s proprietary FluidCrystal® delivery system enables a gel-like encapsulation of buprenorphine under the skin which allows for release over a period of a week or a month.
450 Plymouth Rd, Suite 400
Plymouth Meeting, PA 19462